Treatment Access Solution
A collaboration with Novartis
The Max Foundation has partnered with Novartis since 2008 to increase access to Tasigna® (nilotinib) for chronic myeloid leukemia ( ) patients. Currently the Tasigna® partnership extends to specific low and middle-income countries. Patients must meet the medical criteria and program guidelines.
View our global map and click on individual countries to learn where these programs are operating today. Contact us for more information about how to access Tasigna® (nilotinib) for chronic myeloid leukemia in these countries.